

RESEARCH

Open Access

Fixed dose artesunate amodiaquine – a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine

Bernhards Ogutu¹, Elizabeth Juma², Charles Obonyo², Vincent Jullien^{3,4}, Gwenaëlle Carn⁵, Michel Vaillant⁶, Walter Robert John Taylor⁷ and Jean-René Kiechel^{5*}

Abstract

Background: Pharmacokinetic (PK) and pharmacodynamic (PD) data are limited for artesunate (AS) and amodiaquine (AQ) in uncomplicated *Plasmodium falciparum*.

Methods: From 2007-8, 54 *P. falciparum*-infected, Kenyan adults were assigned randomly fixed dose (FD) ASAQ (n = 26) or non-fixed (NF) ASAQ (n = 28). Total doses were 600 mg AS (both arms) + 1,620 mg (FD) or 1,836 mg (NF)AQ. Follow-up extended over 28 days. PK data were collected for AS, dihydroartemisinin (DHA), AS + DHA combined as DHA equivalents (DHAeq), AQ, desethylamodiaquine (DAQ), and their relationships assessed against the PD collected data consisting of parasitological efficacy, adverse events (AEs), and the Bazett's corrected QT interval (QTcB).

Results: Mean AUC 0-72 of dihydroartemisinin equivalents (DHAeq) when administered as a fixed dose (FD) compared to NF dose were similar: 24.2 ± 4.6 vs 26.4 ± 6.9 $\mu\text{mol} \cdot \text{h/L}$ ($p = 0.68$). Parasite clearance rates were also similar after 24 hrs: 17/25 (68%) vs 18/28 (64.3%) ($p = 0.86$), as well as at 48 hrs: 25/8 (100%) vs 26 (92.9%)/28 ($p = 0.49$). Mean FD vs NF DAQ AUC₀₋₂₈ were 27.6 ± 3.19 vs 32.7 ± 5.53 $\text{mg} \cdot \text{h/L}$ ($p = 0.0005$). Two PCR-proven new infections occurred on Day (D) 28 for estimated, *in vivo*, DAQ minimum inhibitory concentrations of 15.2 and 27.5 ng/mL. Combining the FD and NF arms, the mean QTcB at D2+4 hrs increased significantly ($p = 0.0059$) vs baseline: 420 vs 410 ms ($\Delta = 9.02$ (95% confidence interval 2.72-15.31 ms), explained by falling heart rates, increasing DAQ concentrations and female sex in a general linear mixed effects model. Ten of 108 (9.26%) AEs (5/arm) reported by 37/54 (68.5%) patients were possibly or probably drug related. Severe, asymptomatic neutropaenia developed in 2/47 (4.25%) patients on D28: 574/ μL (vs D0: 5,075/ μL), and 777/ μL (vs D0: 3,778/ μL).

Conclusions: Tolerability of both formulations was good. For QTcB, a parameter for ECG modifications, increases were modest and due to rising DAQ concentrations and falling heart rates as malaria resolved. Rapid parasite clearance rates and no resistant infections suggest effective pharmacokinetics of both formulations.

Keywords: Malaria, Amodiaquine, ECG, Kenya, Pharmacokinetics

* Correspondence: jean-rene.kiechel@wanadoo.fr

⁵Drugs for Neglected Diseases initiative, Geneva, Switzerland

Full list of author information is available at the end of the article

Background

Fixed dose (FD)artesunate-amodiaquine (ASAQ)was developed, WHO prequalified, and registered by a consortium coordinated by the Drugs for Neglected Diseases *initiative* (DNDi)[1,2]. Dosing is straightforward and based on four optimized, age/weight categories [3] which provides greater dosing accuracy than coblistered ASAQ [4] and good adherence [5]. As of 2014, ASAQ is available for use in 35 countries, including 32 in Africa [6]. Where tested in Africa, FD ASAQ has consistently achieved high efficacy, achieving Day 28 cure rates of ~93, 94 and 100% in children ≤60 months of age from Burkina Faso [6], Benin [5] and Central African Republic [10], respectively; ~98% in children <eight years of age in Cote D'Ivoire, Cameroon and Senegal [7] and <five years of age in the Democratic Republic of Congo (DRC) [8], as well as 100% in Nigerian children <12 years of age [9]. FD ASAQ was non-inferior to artemether-lumefantrine (AL) in two trials, achieving cure rates exceeding ~95% and non-inferiority margins of 3% [8,11]. Non-fixed (NF) dose ASAQ has also achieved high cure rates across Africa [12-26] with some reports of efficacy <90% in focal parts of DRC, Tanzania, Sierra Leone, and Rwanda [26-29].

ASAQ is generally well tolerated and, across a range of studies, has a broadly similar adverse event (AE) profile as AL [5,9,11,30,31]. However, one study found significantly higher rates of fatigue, nausea, vomiting, and anaemia in the FD ASAQ arm compared to AL [32]. In this study, the relationship between Day (D)7 desethylamodiaquine (DAQ) concentrations and AE varied with age: a higher median D7 DAQ was associated with fatigue in children under the age of five, and vomiting in those aged ≥ five years of age. Rates of early vomiting or of rejecting the tablets (i.e., spitting them out) were low (0.2 to 6%) [6,11,32], and more common in children under five years old [DNDi data on file [11,32]].

In the past, AQ as malaria prophylaxis caused significant and sometimes fatal hepatotoxicity, which sometimes occurred with severe neutropaenia [33-35]; AQ is no longer used as malaria prophylaxis. Increases in liver enzymes following treatment with ASAQ or AL appear more likely in chronic hepatitis B carriers and were independent of DAQ concentrations [32]. AE rates of all grades for increased concentrations of aspartate and alanine aminotransferase (AST and ALT) ranged from 3 to 8% in both FD ASAQ and AL recipients [32]. Grade 3 (>5-20 × upper limit of normal (ULN)) and grade 4 (>20 ULN) hepatotoxicity was rare and occurred in only 4/496 (0.8%) of patients aged > five years, not quite significantly higher (p = 0.06) than in AL-treated patients 1/502 (0.2%) [32], and in 1/529 (0.19%) of children ≤60 months of age from Burkina Faso [6]. Rates of all grade neutropaenia in patients aged > five years were 19

and 21% in 496 FD ASAQ and 502 AL recipients, respectively; corresponding rates in children < five years of age were lower: 4% (n = 149) and 5.3% (n = 150) [32] respectively. Furthermore, repeated use of ASAQ in 208 malaria-infected children from Uganda over two years (median number of treatments = 16) showed a similar AE profile to 205 children who received repeat dose AL (median number of treatments = 15). The incidence (ASAQ vs AL) of moderate/severe hepatic dysfunction and severe neutropaenia was low in both cohorts: five vs three episodes and two vs one episode, respectively.

Available cardiac data on AQ and ASAQ are very limited. Ngousse *et al.* found clinically insignificant prolongation of PR, QRS and the Bazett's corrected QT interval (QTcB) in *Plasmodium falciparum*-infected adults, and no relationship between the QTcB and DAQ concentrations at 52 hours, the mean time for maximal DAQ concentrations [36]. Similarly, Adjei *et al.* failed to find a positive relationship between DAQ concentrations and either the D3 QTcB or the D3-D0 change in QTcB in African children and adolescents [37]. The lack of an apparent association between QTcB and DAQ concentrations suggest a disease effect on the QTcB but does not exclude definitively a DAQ-related cardiac effect. Intravenous AQ produced QRS interval prolongation in six out of seven healthy, Thai adult volunteers, but no significant changes in heart rate, PR or corrected QT intervals [38]. DAQ was not detected at any time, suggesting AQ caused the slowing of intracardiac conduction.

As part of the development of FD ASAQ, a phase IIb pharmacokinetic and safety study was conducted to complement population pharmacokinetic (PK) data from the phase III trial [39] and to explore PK and pharmacodynamic (PD) relationships.

Methods

Study design and site subject eligibility criteria

The study was an open label, phase IIb, randomized, controlled trial comparing the safety, population PKs, and efficacy of FD ASAQ and NF ASAQ. The study was conducted between November 2007 and June 2008 in the Chulaimbo Sub-District Hospital in Kisumu, western Kenya. This area has intense transmission of chloroquine-, AQ-, and sulphadoxine-pyrimethamine- resistant *P. falciparum* [40-42] as well as significant malaria-related anaemia [43]. In 2007, NF ASAQ had a polymerase chain reaction (PCR)-corrected failure rate of just under 10% in children in the same area [44]. The protocol was approved by the Kenya Medical Research Institute (KEMRI) Ethical Review Committee. This study was conducted in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki. Written informed consent was obtained from patients or an independently witnessed thumb print, as appropriate.

Inclusion/exclusion criteria

Fully informed, consenting patients aged 18 to 60 years presenting with acute, uncomplicated *P. falciparum* with an asexual parasitaemia of $>1,000$ parasites/ μL and either a history of fever or a measured temperature of $\geq 37.5^\circ\text{C}$ in the preceding 24 hours were enrolled. Exclusion criteria were (i) mixed *Plasmodium* infection; (ii) pregnancy (urine test for human chorionic gonadotrophic hormone (βHCG) or lactation); (iii) clinical and/or laboratory features of severe malaria; (iv) severe malnutrition; (v) a concomitant febrile illness of any cause; (vi) significant known comorbidities e.g., cardiac, renal, hepatic diseases, HIV/AIDS; (vii) hypersensitivity to AS or AQ; (viii) an ECG abnormality requiring urgent treatment; (ix) splenectomy; and, (x) ingestion of an artemisinin in the previous three days and/or ingestion of sulphadoxine-pyrimethamine in the previous seven days.

Randomization and treatment

Patients were computer randomized to either FD ASAQ or NF ASAQ before the trial. Treatment regimens were contained in opaque, sealed envelopes in a locked cabinet and were opened after randomization to ensure adequate concealment of drug allocation. Supervised dosing followed the manufacturer's recommendations: (i) FD: two ASAQ tablets/day for three days; one tablet contains AS 100 mg and AQ 270 mg (*sanofi-aventis*, France; batch number 0002, expiry date June 2008) for a total dose of 600 mg AS and 1,620 mg AQ; (ii) NF: AS 200 mg/day (four tablets of 50 mg Arsumax[®] (*sanofi-aventis*, France; batch number 060504, expiry date May 2008) + AQ 612 mg/day (four tablets 153 mg Flavoquine[®] (*sanofi-aventis*, France; batch number 417, expiry date July 2009) for three days, giving total doses of 600 mg AS and 1,836 mg AQ. Patients were observed for 1 hour after drug administration. A repeat dose was administered if there was early vomiting during this time. No concomitant food was given.

Study procedures

At baseline (D0), medical and drug histories were taken, physical examinations performed, Giemsa stained thick and thin blood films were made and blood samples obtained (see below). Thick films were examined and reported as the number of parasites (N)/200 white blood cells (WBCs), converted to N/ μL by assuming a total WBC count of 8,000 cells/ μL . A negative film was declared when the examination of 1,000 WBCs did not reveal any asexual parasites. Basic clinical examinations were performed and malaria blood film slides prepared on D1, 2, 3, 7, 14, 21, and 28. Standard 12 lead ECGs were performed on D0 pre-dose, D0 + 2 hours, D0 + 4 hours, D2 + 2 hours, D2 + 4 hours and D28. Women

underwent urine pregnancy testing at screening and on D28.

Blood sampling

Full blood counts and liver function tests were performed on D0 (pre-dose), D7 and D28, and repeated as clinically indicated. Blood samples for drug concentrations were taken from each patient at the following fixed days: D0 (pre-dose), D7, D14, D21, D28, and also randomly at the following time points: 0.25, 0.50, 1, 1.5, 2, 4 hours post-dosing on D0, and at 0.25, 0.50, 1, 1.5, 2, 4 hours on D2.

Two to three drops of blood were collected on a 3 MM filter paper (Whatman, UK) on D0, D7, D14, D21, and D28 for genotyping by PCR of three genetic markers: merozoite surface proteins (*msp1* and *msp2*) and glutamate rich protein (*glurp*). Genotyping was done for patients with recurrent infections (day of recurrence). A new infection was diagnosed if any one of the three alleles at baseline and recurrence was different; a resistant infection was diagnosed if alleles were shared at baseline and recurrence [45].

Treatment outcomes

The WHO classification of treatment outcomes was used [46]. Early treatment failure (ETF) was defined as (i) the development of danger signs or severe malaria on D1, 2 or 3 in the presence of parasitaemia; (ii) parasitaemia on D2 greater than on D0 irrespective of oral temperature; and, (iii) parasitaemia on D3 with oral temperature $\geq 37.5^\circ\text{C}$; (iv) parasitaemia on D3 $\geq 25\%$ of the count on D0. Late clinical failure (LCF) was defined as (i) development of danger signs or severe malaria after completing the full course of drug administration (D4-D28) in the presence of parasitaemia, without meeting ETF criteria previously; and, (ii) presence of parasitaemia and an oral temperature $\geq 37.5^\circ\text{C}$ after completing the full course of drug administration (D4-D28). Late Parasitological Failure (LPF) was defined as the presence of parasitaemia from D7-D28 and an oral temperature $< 37.5^\circ\text{C}$ without meeting ETF and LCF criteria previously. Adequate clinical and parasitological response (ACPR) was defined as the absence of parasitaemia on D28 irrespective of oral temperature and not having previously met ETF, LCF or LPF criteria.

Rescue treatment

Patients who either failed treatment or required alternative treatment because of an AE were treated with either oral AL or intravenous quinine, as clinically indicated.

Adverse events

An AE was defined as a new symptom, sign, clinical syndrome, or laboratory result that developed or worsened

following drug administration [47] and was graded 1 to 4 (mild, moderate, severe, very severe respectively), according to the National Cancer Institute Toxicity Table [18]. Locally defined, normal laboratory ranges were used to grade laboratory AEs. AE drug relationships were determined by the physicians as unrelated, unlikely, possible, probable, and very probable. A serious AE was one of the following: (i) life-threatening event; (ii) death; (iii) hospitalization or prolongation of hospitalization; (iv) disability or incapacitation; and, (v) congenital anomaly. The following AEs were sought at each assessment: headache, weakness, anorexia, nausea, abdominal pain, itching, vomiting, diarrhoea, rhinitis, cough, vertigo, and the presence of a rash. Individual AE frequencies were modelled with a logistic model with the DAQ AUC₀₋₂₈ (not log-transformed) as covariate. Odds Ratios and 95% confidence intervals were estimated for each AE per 1 unit increase in DAQ AUC₀₋₂₈.

Statistical analysis

A sample size calculation was not determined but based on a similar phase IIb study [48,49], a sample size of 25 patients per arm was considered adequate to demonstrate the disposition of AS, dihydroartemisinin (DHA), AQ and DAQ of the two formulations and to model the rate corrected QT intervals. Treatment efficacy was determined with PCR correction of recurrent parasitaemia and excluded all patients who did not complete follow-up to D28. The safety analysis included all patients who had received at least one dose of the study drug. Data were described as frequencies (proportion), median (range) or mean (standard deviation). Proportional data were compared by Chi-squared or Fisher's exact test, as appropriate. Wilcoxon rank sum/sign rank (skewed data) or unpaired/paired 't' tests (normally distributed data) were used for continuous data (SAS v 19.1.3 software (SAS Institute, Cary, NC, USA). All tests were two-tailed and a p value of ≤ 0.05 was considered statistically significant.

Pharmacokinetic methods and analysis

Plasma samples were analysed using liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) methods developed and validated by SYNEXEL Research International. AQ and DAQ were analysed by reversed-phase liquid chromatography (X Terra C18 MS -3.5 μm ; 50 mm \times 3 mm id) and MS/MS (Sciex API3000) detection in the Turbo Ion Spray positive mode. AS and DHA and the internal standard (AST-D4) were analysed by reversed-phase LC-MS/MS in the Turbo Ion Spray positive mode.

AS/DHA and AQ/DAQ concentration-time data were analysed by use of the First-Order method with Interaction of the non-linear mixed effects modelling program

NONMEM (version VI, version 2.0, double precision). Population PK modelling of AQ/DAQ was reported elsewhere [50]. Concentrations below the LOQ were removed from the database. AS and DHA concentrations were fitted simultaneously, as it was the case for AQ/DAQ. Several structural pharmacokinetic models were investigated. Classical one- and two-compartment models with first order absorption were evaluated for AS and AQ. The transformations of AS into DHA and of AQ into DAQ were assumed to be linear processes. One and two compartment models were evaluated to describe the disposition of AS, DHA, AQ and DAQ. Because it was not identifiable, central distribution volumes of DHA and DAQ were fixed to 1 L. Several error models (i.e., proportional, exponential, and additive random effects model) were also investigated as means of describing interpatient and residual variabilities. Systematic testing for the influence of continuous covariates on the pharmacokinetic parameters was done by use of a generalized model, according to the following equation, by using, for example, *CL/F* and *BW*:

$$CL/F = TV(CL/F) \times \left(\frac{BW}{medianBW} \right)^\theta$$

where *TV(CL/F)* was the typical value of the apparent clearance for a patient with the median covariate value, and θ was the influential factor for body weight.

The influence of binary covariate (Dosage Form, sex, ALAT) was investigated as follows:

$$CL/F = TV(CL/F) \times \theta$$

where θ was equal to the influential factor for Fixed Dose Combination, Men, ALAT > 30 U/L, and was otherwise fixed to 1.

The significance of a relationship between a pharmacokinetic parameter and a covariate was assessed by use of the chi-square test of the difference between the objective functions of the basic model (without the covariate) and the model with the covariate. A covariate was retained in the model if it produced a minimum decrease in the objective function of 3.64 units ($P = 0.05$, 1 degree of freedom) and if its effect was biologically plausible. An intermediate multivariate model that included all selected covariates was then obtained. A covariate was retained in the final multivariate model if its deletion from the intermediate model led to a 6.63-point increase in the objective function ($P = 0.01$, 1 degree of freedom). At each step, the goodness of fit was evaluated by use of a graph of the weighted residuals versus time after administration of the dose (time) or versus the predicted concentrations.

The accuracy and robustness of the final population models were assessed by normalized prediction errors

and visual predictive checks. The final population model parameters were used to perform 200 simulations of the database. The 2.5th and the 97.5th percentiles as well as the 50th (median) of simulated concentrations were plotted against observed concentrations.

Individual Bayesian estimates of the PK parameters were used to calculate individual areas under the curve (AUC) and elimination half-lives ($T_{1/2}$). Individual AUC values of AS and DHA, expressed in $\mu\text{mol}\cdot\text{h}/\text{L}$, were combined in order to obtain DHA equivalents (DHAeq).

ECG analysis

All ECGs were read and analysed by a clinical research organization, according to a prospectively designed analytical plan. ECG intervals were measured using on-screen callipers, as previously described [49]. The QT interval was corrected using three correction formulae: (i) Bazett's $QTcB = QT/RR^{0.5}$; (ii) Fridericia's $QTcF = QT/RR^{0.33}$; and, (iii) a new correction for malaria patients: $QTcN = QT/RR^{0.4}$ defined in the cited paper [51]. A separate paper will detail the cardiac findings. Here only the $QTcB$ is reported. A linear mixed effects model explored

the relationships between the $QTcB$ interval over time with age, sex, treatment, temperature, AQ and DAQ concentrations, and heart rate taken as fixed factors, and a random intercept.

Role of the sponsor

The study was funded by the DNDi which was involved in all aspects of the study, e.g., protocol development, study oversight, data review, and intellectual contribution to this publication.

Results

A total of 54 patients were randomized, 26 to the FD ASAQ arm and 28 to the NF ASAQ arm. All but one patient (FD ASAQ arm) completed their treatment, four patients were lost to follow-up, and there were two late treatment failures (Figure 1). Patient baseline characteristics were similar in the two groups with the exception of the absolute neutrophil and monocyte counts (Table 1).




Figure 1 Trial profile.

Table 1 Patient characteristics

Characteristic	FD ASAQ	NF ASAQ	P value
	N = 26	N = 28	
Age	23.1 (17.9-60.1)	24.2 (18.1-56.9)	0.98
Gender (n, M/F)	12/14	13/15	0.98
Luo ethnic group [N(%)]	23 (88.5)	24 (85.7)	1.00
Symptoms [N(%)]			
Headache	23 (88.5)	26 (92.9)	0.66
Anorexia	18 (69.2)	14 (50.0)	0.15
Nausea	16 (61.5)	17 (60.7)	0.95
Weakness	13 (50.0)	15 (53.6)	0.79
Vomiting	12 (46.2)	16 (57.1)	0.42
Abdominal pain	10 (38.5)	13 (46.4)	0.55
Diarrhoea	3 (11.5)	6 (21.4)	0.47
Cough	1 (3.8)	4 (14.3)	0.35
Signs (range)			
Weight (kg)	58.0 (50.0-90.0)	60.0 (39.0-82.0)	0.78
Temperature (°C)	37.2 (36.0-39.0)	37.2 (35.8-40.0)	0.42
Pulse rate (beats/min)	92.5 (62.0-124.0)	90.5 (57.0-131.0)	0.90
Systolic blood pressure (mmHg)	119.5 (90.0-157.0)	125.5 (85.0-160.0)	0.48
Diastolic blood pressure (mmHg)	70.0 (55.0-92.0)	74.0 (51.0-99.0)	0.37
Palpable spleen	0	1/27 (3.7)	1.0
Palpable liver	0	0	-
Laboratory results (range)			
Asexual parasitaemia/μL	18,479 (8,927-33,915)	13,742 (5,069-23,948)	0.56
Gametocyte carriage (n, %)	1 (3.8)	0 (0.0)	0.48
Haemoglobin (g/dL)	13.3 (10.3-17.6)	13.2 (9.9-17.7)	0.53
White blood cells (× 10 ³ /μL)	5.6 (5.2-6.8)	5.1 (2.3-9.5)	0.09
Neutrophils (× 10 ³ /μL)	3.5 (1.3-5.6)	2.6 (0.8-8.1)	0.02
Lymphocytes (× 10 ³ /μL)	1.3 (0.5-2.5)	1.3 (0.5-3.3)	0.22
Monocytes (× 10 ³ /μL)	0.8 (0.6-1.1)	0.6 (0.4-0.8)	0.005
Eosinophils (× 10 ³ /μL)	0.07 (0.03-0.58)	0.08 (0.05-0.19)	0.60
Platelets (× 10 ³ /μL)	96.0 (44.0-229.0)	95.5 (18.0-254.0)	0.86
AST* (IU/L)	28.0 (13.4-82.9)	31.2 (15.1-56.1)	0.99
ALT* (IU/L)	21.6 (10.5-123.1)	23.2 (3.8-105.9)	0.37
Total bilirubin (μmol/L)	12.0 (1.7-50.6)	13.1 (0.0-65.3)	0.74
Creatinine (μmol/L)	70.7 (17.7-113.2)	75.6 (53.0-114.9)	0.26

All continuous data are expressed as median (range).

*AST – aspartate aminotransferase, ALT- alanine aminotransferase.

Pharmacokinetics

The mean administered doses of AS (± SD) were similar (p = 0.56) for both arms: (i) 3.5 ± 0.11 for the FD vs 3.42 ± 0.008 mg/kg/d for the NF dose but were significantly lower for AQ (p = 0.001) in the FD arm: 9.24 ± 0.23 I

Table 2 Population estimates of the base and the final model for AS/DHA

Parameter	Base model		Final model	
	Mean	Standard error	Mean	Standard error
Ka _{AS} (h ⁻¹)	2.45	0.34	2.41	0.34
CL/F _{AS} (L/h)	797	102	616	98.4
V/F _{AS} (L)	119	51.8	85.2	36.0
FM(%)	0.81	0.16	0.00781	0.00108
Kem (h ⁻¹)	0.819	0.266	0.742	0.166
ΘBW _{kem}	NA	NA	1.65	0.46
ΘFORM	NA	NA	1.79	0.36
ω ² CL/F _{AS}	0.101	0.089	NE	NE
ω ² V/F _{AS}	1.94	2.23	2.21	2.27
ω ² kem _{DHA}	0.000352	0.0666	NE	NE
σ ² ad _{AS}	0.000218	0.000122	0.000277	0.00015
σ ² mult _{AS}	0.665	0.154	0.674	0.116
σ ² ad _{DHA}	0.0438	0.0299	0.0324	0.0223
σ ² mult _{DHA}	0.391	0.093	0.374	0.0726

Ka_{AS}: absorption rate constant of AS, CL/F_{AS}: apparent clearance of AS, V/F_{AS}: apparent distribution volume of AS, FM: fraction of AS metabolized into DHA, K₃₄ and K₄₃: distribution rate constants of DAQ, Kem: elimination rate constant of DHA, ΘBW_{kem}: influential factor of BW on DHA kem, ΘFORM: influence of dosage form on AS bioavailability, ω²CL/F_{AS}: interindividual variability of CL/F_{AS}, ω²V/F_{AS}: interindividual variability of V/F_{AS}, σ²mult_{AS}: proportional residual error for AS, σ²ad_{AS}: additive residual error for AS, σ²mult_{DHA}: proportional residual error for DHA, σ²ad_{DHA}: additive residual error for DHA, NA: Not Available, NE: Not Estimated.

10.73 ± 0.34 mg/kg/d for an absolute mean and relative difference of 1.49 (95% CI 0.6-2.34) mg/kg/d and 16.1% (95% CI 6.8-25.4).

The final AQ model was a one-compartment model with first-order absorption for AQ and an irreversible transformation to DAQ; DAQ disposition was characterized by a two-compartment model. Body weight was the only significant covariate to explain the inter-individual variability of the V/F of AQ and the elimination rate constant of DAQ [50].

The mean DAQ AUC₀₋₂₈ values were FD 27.6 ± 3.2 vs NF 32.7 ± 5.5 mg*h/L (p = 0.0005), a mean difference of 15.6%. This difference became non-significant (p = 0.73) when the DAQ AUC₀₋₂₈ was divided by the total dose of AQ administered in mg: 0.051 ± 0.006 vs 0.053 ± 0.009 mg*h/L/mg AQ. Mean FD and NF half-lives were similar between the two arms: 204 ± 22 vs 214 ± 37 hours (p = 0.58), respectively.

The final AS/DHA model was a 1-compartment model with first-order absorption for AS, and first-order and irreversible transformation into DHA. Disposition of DHA was characterized by a 1-compartment model with first-order elimination.

Body weight was found to explain the interindividual variability of the elimination rate constant of DHA (kem). However, once this covariate included, the interindividual

variability of kem could not be estimated and was therefore removed from the model. Dosage form was found to influence AS bioavailability. Indeed, the bioavailability of AS was 79 % higher with the loose form. The values of the population parameters for AS/DHA for the base and final model are displayed in Table 2.

Lack of bias of the Final Model was evidenced on the graphs displaying the normalized prediction errors versus population predicted concentrations or time after dose (Figure 2). Goodness of fit and lack of bias was also evidenced by the Visual Predictive Checks (Figure 3). Indeed, the AS and DHA observed concentrations were symmetrically distributed around the median of the simulated concentrations and 4.9% of the observed AS concentrations and 7.6% of the observed DHA concentrations were outside the 95% non-parametric confidence interval that was built on the simulated concentrations.

The AUC_{0-72} values as DHAeq were similar (mean and standard deviation) between the two forms: 24.2 ± 4.6 (FD) and 26.4 ± 6.9 (NF) $\mu\text{mol.h/L}$ ($p = 0.68$).

Adverse events

Over 28 days, a total of 37/54 (68.5%) patients reported a total of 108 AEs: 18/26 (69.2%) FD vs 19/28 (67.9%) NF ($p = 0.9$). Ten AEs (five/arm:19.2% FD, 17.9% NF) were considered to be possibly or probably related to ASAQ treatment (Table 3). Early vomiting requiring redosing occurred in one (3.8%) FD recipient and another FD-treated patient developed an aphtous ulcer, but was not neutropaenic during the study. Absolute neutrophil counts ranged from 2,618 to 3,526 neutrophils/ μL blood.

There was no relationship between the DAQ AUC_{0-28} and the odds of reporting headache, weakness, anorexia, nausea, vomiting, abdominal pain, or itching (Additional file 1).

One NF-treated female had two serious AEs. She was admitted to hospital for symptomatic recurrent *P. falciparum* malaria (40,365 parasites/ μL) on D28 and was treated with AL. She was also thought to have typhoid fever and was treated empirically with oral ciprofloxacin. No deaths were reported.





Figure 2 Normalized Prediction Errors (npde) versus time after dose (T1, hours), or predicted concentrations (PRED, mg/L).



Biochemical and haematological parameters

Because the differences in the haematological and biochemical parameters between the arms were not statistically different, they have been combined (Table 4). Over time, the mean haemoglobin (Hb) concentration nadired on D7, rising thereafter, but was significantly lower on D28 vs. baseline. The mean neutrophil and monocyte

counts declined significantly over time whilst the mean lymphocyte and eosinophil counts increased significantly. One patient (NF) had severe neutropaenia of 795 neutrophils/ μL at baseline, which rose to 1,200 neutrophils/ μL by D28. Two out of 47 (4.25% (95% CI: 0.5 to 14.5%)) patients developed severe (grade 3) neutropaenia on D28: (i) FD: 574/ μL (D0: 5,075/ μL), and (ii) NF: 777/ μL (D0: 3,778/ μL). Both patients were well and afebrile. Six patients had severe D0 thrombocytopenia (platelets $<50 \times 10^3/\mu\text{L}$) which returned to normal by D7 or D28. Of the biochemical values, only the mean total bilirubin declined significantly over time. There were no abnormal AST, ALT or creatinine values throughout the study.

ECG data

A total of 363 ECGs recorded were analysed. Because there were no statistically significant differences in the mean QTcB, median PR and QRS intervals, and mean/median changes between the two arms at any time point, the QTcB data were combined for analysis. QRS intervals remained within the normal range at all time points (Table 5). At D2 + 4 hours, the mean increase in the QTcB over baseline was 9.02 milliseconds (ms) (95% confidence intervals: 2.72-15.31 ms ($p = 0.0059$)). The nonlinear mixed effects modelling identified heart rate (inverse relationship), DAQ concentrations (positive relationship) and female sex (positive relationship) as significant, independent, explanatory variables for the QTcB over time (Table 6).

Efficacy

There were no ETFs in either arm. Two NF ASAQ-treated female patients developed symptomatic, new infections on D28 for PCR-corrected ACPR rates of 24/24 FD and 23/23 NF ($p = 0.49$) patients. Pertinent clinical and PK data for the two new infections were: (i) Patient A: D0 parasitaemia: 16,815 parasites/ μL , D28 parasitaemia: 40,365 parasites/ μL , weight 53 kg, AS dose: 3.7 mg/kg/d, AQ dose: 11.5 mg/kg/d, estimated DAQ AUC_{0-28} 33.23 $\text{mg}^*\text{h/L}$, estimated DAQ concentrations were 27.5 ng/mL (D21) and 11.9 ng/mL (D28), and estimated DAQ $T_{1/2}$ was 212 hours (8.3 days); (ii) Patient B: D0 parasitaemia: 20,860 parasites/ μL , D28 parasitaemia: 19,228 parasites/ μL , weight 44 kg, AS dose: 4.54 mg/kg/d, AQ dose: 13.9 mg/kg/d, estimated AUC_{0-28} 32.77 $\text{mg}^*\text{h/L}$, estimated DAQ concentrations were 15.3 ng/mL (D21) and 9.31 ng/mL (D28), and estimated DAQ $T_{1/2}$ 214 hours (8.9 days).

On D1, persistent parasitaemia was present in 8/25 (32%) FD and 10/28 (35.7%) NF ($p = 0.86$) patients. No FD patient had parasites on D2 compared to 2/28 (7.1%) for the NF ($p = 0.49$) patients. Both patients were aparasitaemic on D3. One patient in the FD and none in the

Table 3 Summary of the solicited treatment emergent adverse events (TEAEs) reported at least once by 37 patients

Description	TEAEs (% of patients)			Possibly or probably drug-related TEAEs (% of patients)		
	FD ASAQ (N = 26)	NF ASAQ (N = 28)	All (N = 54)	FD ASAQ (N = 26)	NF ASAQ (N = 28)	All (N = 54)
At least one TEAE	18 (69.2)	19 (67.9)	37 (68.5)	5 (19.2)	5 (17.9)	10 (18.5)
Headache	10 (38.5)	12 (42.9)	22 (40.7)	-	-	-
Weakness	8 (30.8)	11 (39.3)	19 (35.2)	-	2 (7.1)	2 (3.7)
Anorexia	7 (26.9)	7 (25.0)	14 (25.9)	1 (3.8)	-	1 (1.9)
Nausea	6 (23.1)	8 (28.6)	14 (25.9)	-	-	-
Abdominal pain	6 (23.1)	7 (25.0)	13 (24.1)	1 (3.8)	1 (3.6)	2 (3.7)
Itching	6 (23.1)	3 (10.7)	9 (16.7)	3 (11.5)	2 (7.1)	5 (9.3)
Vomiting	4 (15.4)	2 (7.1)	6 (11.1)	-	-	-
Diarrhoea	2 (7.7)	2 (7.1)	4 (7.4)	-	1 (3.6)	1 (1.9)
Rhinitis	2 (7.7)	2 (7.1)	4 (7.4)	1 (3.8)	-	1 (1.9)
Cough	1 (3.8)	2 (7.1)	3 (5.6)	-	-	-

All FD vs NF ASAQ comparisons were not statistically significant.

NF arm had D0 gametocytes. From D2 to D28, only one FD patient had gametocytes on D14.

Discussion

In this small group of semi-immune Kenyan adults, both ASAQ formulations were well tolerated, produced modest changes in the ECG and were effective for treating acute, uncomplicated, *P. falciparum*. Two patients developed asymptomatic severe neutropaenia on D28.

The AE profile of both ASAQ formulations was similar and clinically reported AEs were unrelated to DAQ exposure; however, there was a trend in the reporting of fatigue and increased DAQ exposure. In their large study, Shramm *et al.* found a positive relationship between D7 DAQ and the reporting of fatigue in children

< five years of age. Itching was reported by ~17% of patients, a higher rate compared to the <1-3% reported in paediatric studies [5,9,11,30], and may be related to adults being better able to express themselves. No patients needed parenteral rescue treatment for persistent drug-induced vomiting and only one patient needed to be redosed. These tolerability data appear more satisfactory than those from young children in whom ~7.5% required redosing [31] and ~2% required parenteral rescue treatment for persistent drug-induced vomiting [6,30].

Asymptomatic, severe neutropaenia was found in two patients (~4%) on D28, both of whom had normal neutrophil counts at baseline. Data on the natural dynamics of neutrophils show that when malaria patients of all ages are treated with a variety of anti-malarial drugs,

Table 4 Summary of mean (standard deviation) and mean changes in haematological and biochemical data

	D0	D7	D28	Δ	p	Δ	p
				D7-D0	D7-D0	D28-D0	D28-D0
Haematology							
Haemoglobin (g/dL)	13.4 (2.1)	12.0 (1.8)	12.6 (1.8)	-1.4	<0.000	-0.8	<0.000
White blood cells*	5.4 (1.4)	6.3 (1.9)	5.6 (2.3)	0.9	0.0012	0.3	0.44
Neutrophils*	3.1 (1.4)	2.6 (1.1)	2.2 (1.5)	-0.4	0.046	-0.9	0.00046
Lymphocytes*	1.3 (0.6)	2.6 (0.9)	2.4 (0.9)	1.2	<0.000	1.0	<0.0000
Monocytes*	0.71 (0.28)	0.66 (0.26)	0.48 (0.24)	-0.05	0.25	-0.22	<0.000
Eosinophils*	0.13 (0.16)	0.37 (0.43)	0.41 (0.47)	0.24	<0.000	0.28	<0.0000
Platelets* [†]	96.0 (18-254)	234 (187-311)	175 (140-213)	126.0	<0.000	81.0	<0.0000
Biochemistry							
AST [‡] (U/L)	32.9 (13.2)	33.0 (18.7)	28.3 (11.0)	1.1	0.68	-4.4	0.0268
ALT [‡] (U/L)	29.5 (21.8)	33.8 (20.8)	22.0 (10.2)	5.7	0.03	-8.1	0.005
Total bilirubin [‡]	16.9 (14.8)	7.2 (7.9)	7.0 (6.6)	-10.0	<0.000	-9.4	0.00014
Creatinine [‡]	73.5 (20.3)	71.8 (17.6)	71.9 (27.4)	-2.3	0.50	-3.4	0.48

*x 10³/μL; [‡]μmol/L; [†]median (range); [‡]AST - aspartate aminotransferase; ALT- alanine aminotransferase.

Table 5 Median (interquartile range) and median changes from baseline of the Bazett's corrected QT interval, heart rate, and PR and QRS intervals for both artesunate amodiaquine arms combined*

Statistical parameter	Median	Lower quartile	Upper quartile	Δ vs D0	p vs D0	Median	Lower quartile	Upper quartile	Δ vs D0	p vs D0
Variable	QTcB interval ms					Heart rate b/min				
D0, pre-dose	410	394	425			92	80	103		
D0 + 2 h	412	398	428	2	0.3652	85	74	98	-5	0.0012
D0 + 4 h	416.5	397	429	3.5	0.2593	79	71	89	-8.5	<.0001
D2, pre-dose	411	388	423	-4.5	0.2551	59	53	64	-35	<.0001
D2 + 2 h	415	393	433.5	3	0.4897	59.5	54	64.5	-36	<.0001
D2 + 4 h	420	400	431	7.5 [†]	0.0059	59	55	65	-31.5	<.0001
D28	398	384	418	-10.5	0.0016	66	59	74	-25	<.0001
Variable	QRS interval ms					PR interval ms				
D0, pre-dose	78	72	88			151.5	140.5	172.5		
D0 + 2 h	82	72	89	2	0.2572	158	146	176	5	0.0061
D0 + 4 h	82	76	88	1.5	0.1122	161	153	175	10	<.0001
D2, pre-dose	84	74	96	2.5	0.0084	163	154	185	12	<.0001
D2 + 2 h	85	79	95.5	6	0.0001	167	155.5	184.5	13.5	<.0001
D2 + 4 h	86	78	95	5	0.0003	172	151	187	15	<.0001
D28	86	76	92	5.5	0.0073	164	147	179	12	<.0001

*Only the QTcB data are normally distributed but the median interquartile ranges are shown for all parameters for clarity.

[†]Corresponding mean 95% confidence intervals are: 9.02 (2.72-15.31) ms.

there is a natural decline in the mean neutrophil count whilst lymphocytes increase post-treatment [52]. Rates of post-treatment neutropaenia of all grades were similar between ASAQ (13%), other ACT (14%) and monotherapy (15%), and the risk of developing neutropaenia was inversely related to age. The rate of severe (grade 3/4) neutropaenia for all drugs combined was 3% with no significant difference between ASAQ and other antimalarial drugs [52]. These data, therefore, do not suggest ASAQ recipients are at a higher risk of developing neutropaenia of any grade compared to other antimalarial drugs. Adjei *et al.* demonstrate an almost identical decline in the mean neutrophil counts over 28 days between NF ASAQ and AL in malaria patients aged up to 14 years [30]. Post-treatment severe neutropaenia is

usually asymptomatic or mildly symptomatic and can last for up to four weeks [11,30].

There was a small but statistically significant increase in the mean QTcB interval of ~9 ms (upper 95%, CI 15 ms), four hours after the last dose of ASAQ, representing a maximum increase of <4% over baseline. This time point corresponds to the mean maximum DAQ concentration and when malaria is resolved/resolving. Indeed, increasing DAQ concentrations and decreasing heart rate were significant explanatory factors along with female sex. The positive relationship between DAQ and QTcB contrasts with the findings of Ngousse *et al.* and Adjei *et al.* who analysed their data by simple correlation - an analysis that may have lacked sensitivity[36,37]. The QTcB increases observed in the treated patients are

Table 6 Final random effects model summarizing the significant, independent factors to explain the changes in the QTcB interval over time

Effect	Sex	Estimate	Standard error	DF	t Value	Pr > t
Intercept		373.06	9.3613	52	39.85	<.00001
Time		-0.016	0.00421	296	-3.8	0.0002
Age		0.4153	0.215	296	1.93	0.0543
Sex	F	20.8761	4.6453	296	4.49	<.00001
Sex	M	0
ECG heart rate		0.1461	0.06916	296	2.11	0.0355
DAQ concentrations		0.02972	0.01026	296	2.9	0.0041

consistent with other malaria studies [49,53-56] and suggest FD ASAQ is cardiac safe at therapeutic doses.

The AS, DHA, AQ, and DAQ population PK-modelled data [50] were consistent with other published studies [39,57-59]. AS bioavailability when administered as a FD was less compared to the NF [50] but DHA_{eqs} were similar. Interestingly, this is consistent with FD AS mefloquine in Thai adults [48] but contrasts with children aged <60 months from Burkina Faso who had similar AS bio-availabilities with the same FD and NF ASAQ formulations used in this study [39]. AS is essentially a prodrug for DHA and both share similar parasitocidal properties. DHA_{eq} is probably a better PK marker, so a reduction in the bioavailability of AS exposure *per se* is of little clinical importance in the initial parasitocidal effect, as shown in the patients who had rapid falls in parasite counts in both arms, consistent with ASAQ-treated children from Burkina Faso [6]. The mean administered AQ dose and consequently the DAQ AUC₀₋₂₈ were significantly lower (~16% lower) in the FD arm compared to the NF arm. FD ASAQ was designed for dosing simplicity across four age/weight bands. The good efficacy record of FD ASAQ across most of Africa supports the use of this simplified dosing regimen [5-7,9,11].

The NF arm had two, symptomatic, new infections on D28, representing a failure of post-treatment prophylaxis in an area of intense transmission of CQ and AQ resistant malaria [44]. *P. falciparum* parasites become visible by light microscopy after an interval of at least six days following sporozoite inoculation. The *in vivo* minimum inhibitory concentrations (MICs) of DAQ for the falciparum parasites in these two patients approximates the D21 DAQ concentrations, estimated at ~15 and ~28 ng/mL. These values are equivalent to ~45 and ~85 nmol/mL and are below and above one definition (≥ 60 nmol/mL) of *in vitro* DAQ resistance [60], suggesting at least one new infection could be DAQ resistant.

Phase IIb studies involve low numbers of patients which limits the ability to detect small differences of given parameters. Nevertheless, the distinct properties in the PK characteristics of the two formulations studied and the key factors affecting the modest increase in QTcB at the time of maximum DAQ concentrations were demonstrated.

Conclusion

This phase II study in adults has demonstrated the cardiac safety of ASAQ at therapeutic doses and similar PK characteristics of AS and DHA. FD ASAQ is a good option where AQ resistance is low or where national malaria control programmes wish to switch from efficacious NF ASAQ to FD ASAQ.

Additional file

Additional file 1: Odds ratio estimates, with Wald 95% confidence intervals, for reporting certain symptoms as adverse events per one unit increase in the desethyl amodiaquine AUC₀₋₂₈.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

BO helped develop the study protocol, executed the study and critically reviewed the manuscript. WRJT developed the study protocol and wrote the first draft of the paper. MV did the PK ECG modelling and contributed to writing the first draft of the paper. JV did the population PK analyses and contributed to the writing of the first draft of the paper. EJ and CO executed the study and critically reviewed the paper. JRK and GC supervised and coordinated the study, and critically reviewed the paper. All authors have read and reviewed the final version of the paper.

Acknowledgements

We are grateful to the patients for participating in the study and the study nurses for their invaluable help. We thank Dr Piero Olliaro for helpful discussions during protocol development; Dr Julie Simpson for help with the population PK sampling; Cardinal Systems for data management and analyses; SYNEXEL Research International SAS for the bioanalytical report; Sanofi-Aventis (now Sanofi) for supplying both ASAQ formulations; Quintiles for reading the ECGs and writing the ECG report and Susan Wells, Karly Louie and Graciela Diap for valuable editorial contributions to this manuscript. DNDi thanks the following donors for supporting this study: the Department for International Development (DFID), UK; Spanish Agency for International Development Cooperation (AECID), Spain; Dutch Ministry of Foreign Affairs (DGIS), The Netherlands; *Médecins Sans Frontières*, International; French Development Agency (AFD), France.

Author details

¹Centre for Clinical Research, Kenya Medical Research Institute, Kisumu, Kenya. ²Centre for Global Health Research, Kenya Medical Research Institute, Nairobi City, Kenya. ³INSERM U1129, University Paris Descartes, CEA Gif-sur-Yvette, France. ⁴Service de Pharmacologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France. ⁵Drugs for Neglected Diseases initiative, Geneva, Switzerland. ⁶Competence Centre in Methodology and Statistics, Public Research Centre for Health, Strassen, Luxembourg. ⁷Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Geneva, Switzerland.

Received: 14 August 2014 Accepted: 6 December 2014

Published: 16 December 2014

References

1. Kiechel JR, Pecoul B: ASAQ, a breakthrough in the fight against malaria. *Med Trop (Mars)* 2007, **67**:109-110.
2. Bompert F, Kiechel JR, Sebbag R, Pecoul B: Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience. *Malar J* 2011, **10**:143.
3. Taylor WR, Terlouw DJ, Olliaro PL, White NJ, Brasseur P, ter Kuile FO: Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malaria. *Bull World Health Organ* 2006, **84**:956-964.
4. Brasseur P, Agnamey P, Gaye O, Cisse M, Badiane M, Vaillant M, Taylor WR, Olliaro P: Dosing accuracy of artesunate and amodiaquine as treatment for falciparum malaria in Casamance, Senegal. *Trop Med Int Health* 2009, **14**:79-87.
5. Faucher JF, Aubouy A, Adeothy A, Cottrell G, Doritchamou J, Gourmel B, Houze P, Kossou H, Amedome H, Massougbedji A, Cot M, Deloron P: Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated *Plasmodium falciparum* malaria in Benin: a randomized effectiveness noninferiority trial. *J Infect Dis* 2009, **200**:57-65.

6. Sirima SB, Tiono AB, Gansane A, Diarra A, Ouedraogo A, Konate AT, Kiechel JR, Morgan CC, Olliaro PL, Taylor WR: **The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated *Plasmodium falciparum*.** *Malar J* 2009, **8**:48.
7. Faye B, Kuete T, Kiki-Barro CP, Tine RC, Nkoa T, Ndiaye JL, Kakpo CA, Sylla K, El Menan H, Gaye O, Same-Ekobo A, Moussa K: **Multicentre study evaluating the non-inferiority of the new paediatric formulation of artesunate/amodiaquine versus artemether/lumefantrine for the management of uncomplicated *Plasmodium falciparum* malaria in children in Cameroon, Ivory Coast and Senegal.** *Malar J* 2012, **11**:433.
8. Espie E, Lima A, Atua B, Dhorda M, Flevaud L, Sompwe EM, Palma Urrutia PP, Guerin PJ: **Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood *Plasmodium falciparum* malaria in Democratic Republic of Congo: a randomized non-inferiority trial.** *Malar J* 2012, **11**:174.
9. Gbotosho GO, Sowunmi A, Okuboyejo TM, Happi CT, Folarin OA, Michael OS, Adewoye EO: **Therapeutic efficacy and effects of artemether-lumefantrine and artesunate-amodiaquine coformulated or copackaged on malaria-associated anemia in children with uncomplicated *Plasmodium falciparum* malaria in Southwest Nigeria.** *Am J Trop Med Hyg* 2011, **84**:813–819.
10. Djalle D, Njuimo SP, Manirakiza A, Laganier R, Le Faou A, Rogier C: **Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxy-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial.** *Malar J* 2014, **13**:9.
11. Ndiaye JL, Randrianarivelojosia M, Sagara I, Brasseur P, Ndiaye I, Faye B, Randrianasolo L, Ratsimbaoa A, Forlemu D, Moor VA, Traore A, Dicko Y, Dara N, Lameyre V, Diallo M, Djimde A, Same-Ekobo A, Gaye O: **Randomized, multicentre assessment of the efficacy and safety of ASAQ—a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated *Plasmodium falciparum* malaria.** *Malar J* 2009, **8**:125.
12. Clark TD, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, Greenhouse B, Staedke SG, Kanya MR, Dorsey G, Rosenthal PJ: **Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children.** *PLoS One* 2010, **5**:e11759.
13. Bonnet M, Roper C, Felix M, Coulibaly L, Kankolongo GM, Guthmann JP: **Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zerekore.** *Malar J* 2007, **6**:54.
14. van den Broek I, Kitz C, Al Attas S, Libama F, Balasegaram M, Guthmann JP: **Efficacy of three artemisinin combination therapies for the treatment of uncomplicated *Plasmodium falciparum* malaria in the Republic of Congo.** *Malar J* 2006, **5**:113.
15. Guthmann JP, Cohuet S, Rigutto C, Fortes F, Saraiva N, Kiguli J, Kyomuhendo J, Francis M, Noel F, Mulemba M, Balkan S: **High efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola.** *Am J Trop Med Hyg* 2006, **75**:143–145.
16. Ibrahim AM, Kheir MM, Osman ME, Khalil IF, Alifrangis M, Elmardi KA, Malik EM, Adam I: **Efficacies of artesunate plus either sulfadoxine-pyrimethamine or amodiaquine, for the treatment of uncomplicated, *Plasmodium falciparum* malaria in eastern Sudan.** *Ann Trop Med Parasitol* 2007, **101**:15–21.
17. Ajayi IO, Browne EN, Bateganya F, Yar D, Happi C, Falade CO, Gbotosho GO, Yusuf B, Boateng S, Mugittu K, Cousens S, Nanyunja M, Pagnoni F: **Effectiveness of artemisinin-based combination therapy used in the context of home management of malaria: a report from three study sites in sub-Saharan Africa.** *Malar J* 2008, **7**:190.
18. Martensson A, Stromberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, Olliaro P, Ali AS, Bjorkman A: **Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood *Plasmodium falciparum* malaria in Zanzibar, Tanzania.** *Clin Infect Dis* 2005, **41**:1079–1086.
19. Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M, Cobelens F, Diallo S, Faucher JF, Garner P, Gikunda S, Kremsner PG, Krishna S, Lell B, Loolpapit M, Matsiegui PB, Missinou MA, Mwanza J, Ntoumi F, Olliaro P, Osimbo P, Rezbach P, Some E, Taylor WR: **Amodiaquine-artesunate versus amodiaquine for uncomplicated *Plasmodium falciparum* malaria in African children: a randomised, multicentre trial.** *Lancet* 2002, **359**:1365–1372.
20. Holmgren G, Hamrin J, Svard J, Martensson A, Gil JP, Bjorkman A: **Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa.** *Infect Genet Evol* 2007, **7**:562–569.
21. Kabanyanyi AM, Mwita A, Sumari D, Mandike R, Mugittu K, Abdulla S: **Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania.** *Malar J* 2007, **6**:146.
22. Hamour S, Melaku Y, Keus K, Wambugu J, Atkin S, Montgomery J, Ford N, Hook C, Checchi F: **Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus amodiaquine combinations.** *Trans R Soc Trop Med Hyg* 2005, **99**:548–554.
23. Bacassamo F, Enosse S, Aponte JJ, Gomez-Olive FX, Quinto L, Mabunda S, Barreto A, Magnussen P, Ronn AM, Thompson R, Alonso PL: **Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria.** *Trop Med Int Health* 2004, **9**:200–208.
24. Ndounga M, Mayengue PI, Casimiro PN, Loumouamou D, Basco LK, Ntoumi F, Brasseur P: **Artesunate-amodiaquine efficacy in Congolese children with acute uncomplicated falciparum malaria in Brazzaville.** *Malar J* 2013, **12**:53.
25. Swarthout TD, van den Broek IV, Kayembe G, Montgomery J, Pota H, Roper C: **Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes.** *Trop Med Int Health* 2006, **11**:1503–1511.
26. Rwagacondo CE, Karema C, Mugisha V, Erhart A, Dujardin JC, Van Overmeir C, Ringwald P, D'Alessandro U: **Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria.** *Trop Med Int Health* 2004, **9**:1091–1098.
27. Bonnet M, Broek I, van Herp M, Urrutia PP, van Overmeir C, Kyomuhendo J, Ndosimao CN, Ashley E, Guthmann JP: **Varying efficacy of artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in the Democratic Republic of Congo: a report of two in-vivo studies.** *Malar J* 2009, **8**:192.
28. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, Greenwood BM, Whitty CJ: **Amodiaquine alone, amodiaquine + sulfadoxine-pyrimethamine, amodiaquine + artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial.** *Lancet* 2005, **365**:1474–1480.
29. Grandesso F, Hagerman A, Kamara S, Lam E, Checchi F, Balkan S, Scollo G, Durand R, Guthmann JP: **Low efficacy of the combination artesunate plus amodiaquine for uncomplicated falciparum malaria among children under 5 years in Kailahun, Sierra Leone.** *Trop Med Int Health* 2006, **11**:1017–1021.
30. Adjei GO, Kurtzhals JA, Rodrigues OP, Alifrangis M, Hoegberg LC, Kitchev ED, Badoe EV, Lamptey R, Goka BQ: **Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up.** *Malar J* 2008, **7**:127.
31. Falade CO, Ogundele AO, Yusuf BO, Ademowo OG, Ladipo SM: **High efficacy of two artemisinin-based combinations (artemether-lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria.** *Trop Med Int Health* 2008, **13**:635–643.
32. Schramm B, Valeh P, Baudin E, Mazinda CS, Smith R, Pinoges L, Sundaygar T, Zolia YM, Jones JJ, Comte E, Bruneel A, Branger M, Jullien V, Cam G, Kiechel JR, Ashley EA, Guérin PJ: **Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated *Plasmodium falciparum* malaria: two open-label, randomized trials in Nimba County Liberia.** *Malar J* 2013, **12**:250.
33. Neftel KA, Woodtly W, Schmid M, Frick PG, Fehr J: **Amodiaquine induced agranulocytosis and liver damage.** *Br Med J (Clin Res Ed)* 1986, **292**:721–723.
34. Orrell C, Taylor WR, Olliaro P: **Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate.** *Trans R Soc Trop Med Hyg* 2001, **95**:517–518.
35. Markham LN, Giostra E, Hadengue A, Rossier M, Rebsamen M, Desmeules J: **Emergency liver transplantation in amodiaquine-induced fulminant hepatitis.** *Am J Trop Med Hyg* 2007, **77**:14–15.

36. Ngouesse B, Basco LK, Ringwald P, Keundjian A, Blackett KN: **Cardiac effects of amodiaquine and sulfadoxine-pyrimethamine in malaria-infected African patients.** *Am J Trop Med Hyg* 2001, **65**:711–716.
37. Adjei GO, Oduro-Boatey C, Rodrigues OP, Hoegberg LC, Alifrangis M, Kurtzhals JA, Goka BQ: **Electrocardiographic study in Ghanaian children with uncomplicated malaria, treated with artesunate-amodiaquine or artemether-lumefantrine.** *Malar J* 2012, **11**:420.
38. White NJ, Looareesuwan S, Edwards G, Phillips RE, Karbwang J, Nicholl DD, Bunch C, Warrell DA: **Pharmacokinetics of intravenous amodiaquine.** *Br J Clin Pharmacol* 1987, **23**:127–135.
39. Stepniewska K, Taylor W, Sirima SB, Ouedraogo EB, Ouedraogo A, Gansane A, Simpson JA, Morgan CC, White NJ, Kiechel JR: **Population pharmacokinetics of artesunate and amodiaquine in African children.** *Malar J* 2009, **8**:200.
40. Obonyo CO, Ochieng F, Taylor WR, Ochola SA, Mugitu K, Olliaro P, ter Kuile F, Oloo AJ: **Artesunate plus sulfadoxine-pyrimethamine for uncomplicated malaria in Kenyan children: a randomized, double-blind, placebo-controlled trial.** *Trans R Soc Trop Med Hyg* 2003, **97**:585–591.
41. Holmgren G, Bjorkman A, Gil JP: **Amodiaquine resistance is not related to rare findings of pfmdr1 gene amplifications in Kenya.** *Trop Med Int Health* 2006, **11**:1808–1812.
42. Zucker JR, Ruebush TK 2nd, Obonyo C, Otieno J, Campbell CC: **The mortality consequences of the continued use of chloroquine in Africa: experience in Siaya, western Kenya.** *Am J Trop Med Hyg* 2003, **68**:386–390.
43. Obonyo CO, Vulule J, Akhwale WS, Grobbee DE: **In-hospital morbidity and mortality due to severe malarial anemia in western Kenya.** *Am J Trop Med Hyg* 2007, **77**:23–28.
44. Thwing JJ, Odera CO, Odhiambo FO, Otieno KO, Kariuki S, Ord R, Roper C, McMorrow M, Vulule J, Slutsker L, Newman RD, Hamel MJ, Desai M: **In-vivo efficacy of amodiaquine-artesunate in children with uncomplicated Plasmodium falciparum malaria in western Kenya.** *Trop Med Int Health* 2009, **14**:294–300.
45. Snounou G, Beck HP: **The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment.** *Parasitol Today* 1998, **14**:462–467.
46. WHO: *Guidelines for the Treatment of Malaria.* Geneva, Switzerland: World Health Organization; 2006.
47. Edwards IR, Aronson JK: **Adverse drug reactions: definitions, diagnosis, and management.** *Lancet* 2000, **356**:1255–1259.
48. Krudsood S, Looareesuwan S, Tangpukdee N, Wilairatana P, Phumratanaprapin W, Leowattana W, Chalermrut K, Ramanathan S, Navaratnam V, Olliaro P, Vaillant M, Kiechel JR, Taylor WR: **New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine.** *Antimicrob Agents Chemother* 2010, **54**:3730–3737.
49. Krudsood S, Looareesuwan S, Wilairatana P, Leowattana W, Tangpukdee N, Chalermrut K, Ramanathan S, Navaratnam V, Olliaro P, Vaillant M, Kiechel JR, Taylor WR: **Effect of artesunate and mefloquine in combination on the Fridericia corrected QT intervals in Plasmodium falciparum infected adults from Thailand.** *Trop Med Int Health* 2011, **16**:458–465.
50. Jullien V, Ogutu B, Juma E, Carn G, Obonyo C, Kiechel JR: **Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy.** *Antimicrob Agents Chemother* 2010, **54**:2611–2617.
51. Price RN, Nosten F, White NJ: **Prolongation of the QTc interval in African children treated for falciparum malaria.** *Am J Trop Med Hyg* 1998, **59**:503.
52. Zwang J, Ndiaye JL, Djimde A, Dorsey G, Martensson A, Karema C, Olliaro P: **Comparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan Africa.** *Malar J* 2012, **11**:25.
53. Gupta RK, Van Vugt M, Paiphun L, Slight T, Looareesuwan S, White NJ, Nosten F: **Short report: no evidence of cardiotoxicity of atovaquone-proguanil alone or in combination with artesunate.** *Am J Trop Med Hyg* 2005, **73**:267–268.
54. Mytton OT, Ashley EA, Peto L, Price RN, La Y, Hae R, Singhasivanon P, White NJ, Nosten F: **Electrocardiographic safety evaluation of dihydroartemisinin piperazine in the treatment of uncomplicated falciparum malaria.** *Am J Trop Med Hyg* 2007, **77**:447–450.
55. Karunajeewa H, Lim C, Hung TY, Ilett KF, Denis MB, Socheat D, Davis TM: **Safety evaluation of fixed combination piperazine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria.** *Br J Clin Pharmacol* 2004, **57**:93–99.
56. van Vugt M, Ezzet F, Nosten F, Gathmann I, Wilairatana P, Looareesuwan S, White NJ: **No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine.** *Am J Trop Med Hyg* 1999, **61**:964–967.
57. Hietala SF, Bhattarai A, Msellem M, Roshammar D, Ali AS, Stromberg J, Hombhanje FW, Kaneko A, Bjorkman A, Ashton M: **Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria.** *J Pharmacokinetic Pharmacodyn* 2007, **34**:669–686.
58. Orrell C, Little F, Smith P, Folb P, Taylor W, Olliaro P, Barnes KI: **Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers.** *Eur J Clin Pharmacol* 2008, **64**:683–690.
59. Navaratnam V, Ramanathan S, Wahab MS, Siew Hua G, Mansor SM, Kiechel JR, Vaillant M, Taylor WR, Olliaro P: **Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers.** *Eur J Clin Pharmacol* 2009, **65**:809–821.
60. Aubouy A, Mayombo J, Keundjian A, Bakary M, Le Bras J, Deloron P: **Lack of prediction of amodiaquine efficacy in treating Plasmodium falciparum malaria by in vitro tests.** *Am J Trop Med Hyg* 2004, **71**:294–296.

doi:10.1186/1475-2875-13-498

Cite this article as: Ogutu et al.: Fixed dose artesunate amodiaquine – a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine. *Malaria Journal* 2014 **13**:498.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

